233 related articles for article (PubMed ID: 21493087)
1. Eribulin -- a review of preclinical and clinical studies.
Swami U; Chaudhary I; Ghalib MH; Goel S
Crit Rev Oncol Hematol; 2012 Feb; 81(2):163-84. PubMed ID: 21493087
[TBL] [Abstract][Full Text] [Related]
2. Eribulin in Cancer Treatment.
Swami U; Shah U; Goel S
Mar Drugs; 2015 Aug; 13(8):5016-58. PubMed ID: 26262627
[TBL] [Abstract][Full Text] [Related]
3. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
Scarpace SL
Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
Mani S; Swami U
Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
[TBL] [Abstract][Full Text] [Related]
5. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
O'Sullivan Coyne G; Walsh J; Kelly CM
Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
8. Eribulin in non-small cell lung cancer: challenges and potential strategies.
Swami U; Shah U; Goel S
Expert Opin Investig Drugs; 2017 Apr; 26(4):495-508. PubMed ID: 28161993
[TBL] [Abstract][Full Text] [Related]
9. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
10. Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.
Seetharam M; Kolla KR; Chawla SP
Future Oncol; 2018 Jul; 14(16):1531-1545. PubMed ID: 29411654
[TBL] [Abstract][Full Text] [Related]
11. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
Polastro L; Aftimos PG; Awada A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
13. Clinical and preclinical features of eribulin-related peripheral neuropathy.
Tarasiuk O; Cavaletti G; Meregalli C
Exp Neurol; 2022 Feb; 348():113925. PubMed ID: 34801586
[TBL] [Abstract][Full Text] [Related]
14. Eribulin.
Perry CM
Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
[TBL] [Abstract][Full Text] [Related]
15. Eribulin mesylate in breast cancer.
Verdaguer H; Morilla I; Urruticoechea A
Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
18. Eribulin: a novel cytotoxic chemotherapy agent.
Preston JN; Trivedi MV
Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cortes J; Montero AJ; Glück S
Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]